. 2009 Jul 8;2009(3):CD007303. doi: 10.1002/14651858.CD007303.pub2

16. Multivariate analyses for overall survival in all cancer patients.

Overall survival all cancer patients	Model 1	Model 2	Model 3	Model 4
Patients included	n=13353	n=11636	n=10599	n=6547
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
ESA vs ctrl unadjusted*	1.06 (95% CI 1.00‐1.12)	1.06 (95% CI 1.00‐1.13)	1.04 (95% CI 0.98‐1.11)	1.07 (95% CI 0.99‐1.15)
ESA vs ctrl adjusted**	1.06 (95% CI 1.00‐1.12)	1.05 (95% CI 1.00‐1.12)	1.04 (95% CI 0.98‐1.11)	1.09 (95% CI 1.01‐1.17)
Hb at baseline
Hb < 8 g/dL	1	1	1	1
Hb 8‐10 g/dL	0.77 (95% CI 0.68‐0.87)	0.72 (95% CI 0.63‐0.83)	0.78 (95% CI 0.68‐0.90)	0.86 (95% CI 0.70‐1.04)
Hb 10‐12 g/dL	0.60 (95% CI 0.52‐0.68)	0.56 (95% CI 0.48‐0.64)	0.62 (95% CI 0.54‐0.71)	0.74 (95% CI 0.60‐0.92)
Hb 12‐14 g/dL	0.48 (95% CI 0.41‐0.56)	0.45 (95% CI 0.38‐0.53)	0.52 (95% CI 0.44‐0.61)	0.71 (95% CI 0.55‐0.93)
Hb > 14 g/dL	0.40 (95% CI 0.33‐0.48)	0.39 (95% CI 0.32‐0.47)	0.44 (95% CI 0.36‐0.54)	0.69 (95% CI 0.48‐0.99)
Age at randomization
18 ‐ 35 yrs	0.82 (95% CI 0.62‐1.07)	0.91 (95% CI 0.68‐1.22)	0.84 (95% CI 0.62‐1.13)	0.65 (95% CI 0.42‐1.00)
35 ‐ 45 yrs	1	1	1	1
45 ‐ 55 yrs	1.06 (95% CI 0.93‐1.21)	1.05 (95% CI 0.91‐1.20)	1.10 (95% CI 0.95‐1.28)	1.16 (95% CI 0.96‐1.40)
55 ‐ 65 yrs	1.13 (95% CI 1.00‐1.28)	1.15 (95% CI 1.01‐1.31)	1.25 (95% CI 1.08‐1.44)	1.32 (95% CI 1.09‐1.58)
65 ‐ 75 yrs	1.23 (95% CI 1.08‐1.39)	1.22 (95% CI 1.07‐1.40)	1.34 (95% CI 1.16‐1.55)	1.34 (95% CI 1.11‐1.62)
> 75 ys	1.32 (95% CI 1.14‐1.53)	1.40 (95% CI 1.19‐1.63)	1.39 (95% CI 1.17‐1.65)	1.31 (95% CI 1.06‐1.63)
Sex
Male	1	1	1	1
Female	0.79 (95% CI 0.73‐0.84)	0.81 (95% CI 0.75‐0.88)	0.80 (95% CI 0.74‐0.86)	0.77 (95% CI 0.70‐0.84)
Tumor category
Hematological malign.	1	1	1	1
Breast cancer	1.91 (95% CI 1.54‐2.37)	1.57 (95% CI 1.15‐2.13)	1.93 (95% CI 1.51‐2.46)	2.05 (95% CI 1.59‐2.65)
Head and neck cancer	2.57 (95% CI 1.87‐3.53)	2.31 (95% CI 1.56‐3.41)	2.56 (95% CI 1.79‐3.65)	3.38 (95% CI 1.96‐5.83)
Lung cancer	4.06 (95% CI 3.31‐4.99)	3.06 (95% CI 2.30‐4.07)	3.79 (95% CI 2.96‐4.86)	3.98 (95% CI 3.07‐5.16)
Gastrointestinal	3.08 (95% CI 2.49‐3.82)	2.90 (95% CI 2.15‐3.90)	3.11 (95% CI 2.42‐4.01)	3.27 (95% CI 2.51‐4.26)
Gynecological	2.19 (95% CI 1.70‐2.82)	1.67 (95% CI 1.20‐2.32)	2.33 (95% CI 1.74‐3.12)	2.86 (95% CI 2.11‐3.88)
Genitourinary	2.76 (95% CI 2.17‐3.50)	2.36 (95% CI 1.72‐3.22)	2.69 (95% CI 2.04‐3.55)	2.90 (95% CI 2.18‐3.87)
Other	3.21 (95% CI 2.55‐4.04)	2.94 (95% CI 2.15‐4.01)	3.24 (95% CI 2.48‐4.24)	3.35 (95% CI 2.52‐4.47)
Tumor stage
Metastatic or advanced	‐	1	‐	‐
Not metastatic/advanced	‐	0.51 (95% CI 0.46‐0.57)	‐	‐
Region
Northern America	‐	‐	1	1
Southern Europe	‐	‐	1.33 (95% CI 1.06‐1.68)	1.27 (95% CI 1.00‐1.61)
Australia & New Zealand	‐	‐	0.97 (95% CI 0.72‐1.31)	0.97 (95% CI 0.71‐1.32)
Eastern Europe	‐	‐	1.50 (95% CI 1.23‐1.82)	1.50 (95% CI 1.22‐1.83)
Northern Europe	‐	‐	1.59 (95% CI 1.29‐1.97)	1.61 (95% CI 1.29‐2.01)
Western Europe	‐	‐	1.47 (95% CI 1.19‐1.82)	1.47 (95% CI 1.18‐1.83)
Other	‐	‐	1.23 (95% CI 0.85‐1.77)	1.51 (95% CI 0.96‐2.37)
BMI
< 19 kg/m²	‐	‐	1	1
19‐25 kg/m²	‐	‐	0.79 (95% CI 0.70‐0.88)	0.82 (95% CI 0.71‐0.94)
25‐30 kg/m²	‐	‐	0.69 (95% CI 0.61‐0.77)	0.70 (95% CI 0.60‐0.81)
> 30 kg/m²	‐	‐	0.61 (95% CI 0.53‐0.71)	0.61 (95% CI 0.51‐0.72)
Hct at baseline
Hct <23.5%	‐	‐	‐	1
Hct 23.5%‐29.4%	‐	‐	‐	0.84 (95% CI 0.63‐1.12)
Hct 29.4%‐35.3%	‐	‐	‐	0.71 (95% CI 0.53‐0.96)
Hct 35.3%‐41.2%	‐	‐	‐	0.61 (95% CI 0.44‐0.85)
>Hct 41.2%	‐	‐	‐	0.48 (95% CI 0.32‐0.72)
Performance score
ECOG 0, 1 or 2	‐	‐	‐	1

*unadjusted HR based on the number of patients included in the respective model   **HR adjusted for the variables outlined in the respective columns